Stockscreener 앱 받기
1.69
24.26%
0.33
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Prime Medicine stock plummets amid restructuring and leadership changes - MSN
Prime Medicine Elects Directors at Annual Meeting - TipRanks
Altria, Prime Medicine, US Steel, DLocal, Prothena: Trending by Analysts - TipRanks
Layoff Tracker: iTeos Winds Down Operations - BioSpace
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty - MSN
Prime Medicine Announces Key Presentations at Two Major Healthcare Investor Conferences in June - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Citigroup Downgrades Prime Medicine (PRME) Amid Significant Pric - GuruFocus
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges By Investing.com - Investing.com South Africa
Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10 - marketscreener.com
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges - Investing.com
Prime Medicine (PRME) Downgraded by Citi with Reduced Price Targ - GuruFocus
Prime Medicine (PRME) Downgraded by Citi with Reduced Price Target | PRME Stock News - GuruFocus
Prime Medicine downgraded to Neutral from Buy at Citi - TipRanks
Hold Rating for Prime Medicine, Inc. Amid Financial Uncertainties and Strategic Adjustments - TipRanks
Hold Rating on Prime Medicine, Inc. Amid Strategic Shifts and Financial Reevaluation - TipRanks
Prime Medicine Executives Make Bold Stock Purchases! - TipRanks
Insider Buying: Ann Lee Acquires 100,000 Shares of Prime Medicine Inc (PRME) - GuruFocus
Prime Medicine Executives Make Significant Stock Purchases - TradingView
Prime Medicine CEO Acquires 125,000 Shares - TradingView
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish - MSN
Prime Medicine Cuts Workforce By 25% In Strategic Shift - Finimize
CEO among 25% of staff out the door at cash-strapped Prime - The Pharma Letter
Prime Medicine (PRME) Sees Price Target Adjustment by JMP Securities | PRME Stock News - GuruFocus
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Prime Medicine (PRME) Receives Downgrade from JP Morgan | PRME Stock News - GuruFocus
PRME: Prime Medicine Downgraded to Neutral by HC Wainwright & Co - GuruFocus
Prime Medicine downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Prime Medicine (PRME) Faces Downgrade Amid Strategic Shift | PRM - GuruFocus
Prime Medicine (PRME) Adjusts Strategy Amid Leadership Changes | - GuruFocus
Prime Medicine price target lowered to $6 from $10 at Citizens JMP - TipRanks
Prime Medicine, Inc.: Hold Rating Amid Strategic Restructuring and Long-term Uncertainty - TipRanks
Prime Medicine refocuses on liver disease, leadership changes By Investing.com - Investing.com South Africa
PRME Downgraded by JPMorgan Amid Strategic Shift | PRME Stock News - GuruFocus
Prime Medicine Chops 25% of Workforce, Pivots Pipeline as CEO Quits - Genetic Engineering and Biotechnology News
Prime Medicine downgraded to Neutral from Overweight at JPMorgan - TipRanks
Prime Medicine to deprioritize CGD programs, reduce headcount by 25% - TipRanks
6 Analysts Assess Prime Medicine: What You Need To Know - Benzinga
CRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staff - The Boston Globe
Jefferies cuts Prime Medicine stock target to $9, maintains Buy By Investing.com - Investing.com Canada
Chardan Lowers Price Target on Prime Medicine to $12 From $16, Keeps Buy Rating - marketscreener.com
David Liu gene-editing startup cuts staff, names new CEO - The Business Journals
PRME: Chardan Capital Adjusts Price Target for Prime Medicine | - GuruFocus
Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT Stock News - GuruFocus
Prime Medicine price target lowered to $12 from $16 at Chardan - TipRanks
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish By Stocktwits - Investing.com India
Wedbush Adjusts Prime Medicine Price Target to $8 From $13, Maintains Outperform Rating - marketscreener.com
Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot - BioPharma Dive
Prime Medicine CEO Keith Gottesdiener to step down, Allan Reine to succeed - TipRanks
Prime Medicine Prioritizes Pipeline, Cuts Workforce By 25%Stock Plunges - Nasdaq
Prime Medicine (PRME) Shares Plunge Amid Leadership Change and Strategic Shift - GuruFocus
Prime Medicine stock plummets amid restructuring and leadership changes By Investing.com - Investing.com South Africa
1.21%
1.51%
자본화:
|
볼륨(24시간):